Download Research in neurodegenerative diseases: challenges and solutions

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts

Haemodynamic response wikipedia , lookup

Psychoneuroimmunology wikipedia , lookup

Neurogenomics wikipedia , lookup

Molecular neuroscience wikipedia , lookup

Aging brain wikipedia , lookup

National Institute of Neurological Disorders and Stroke wikipedia , lookup

Blood–brain barrier wikipedia , lookup

Neuropsychopharmacology wikipedia , lookup

Impact of health on intelligence wikipedia , lookup

Alzheimer's disease wikipedia , lookup

Clinical neurochemistry wikipedia , lookup

Biochemistry of Alzheimer's disease wikipedia , lookup

Transcript
ADMET & DMPK 3(3) (2015) 154; doi: 10.5599/admet.3.3.217
Open Access : ISSN : 1848-7718
http://www.pub.iapchem.org/ojs/index.php/admet/index
Editorial
Research in neurodegenerative diseases: challenges and
solutions
Kin Tam
Editor: ADMET & DMPK
E-mail: [email protected]
The need of effective medicines for the treatment of neurodegenerative diseases, such as Alzheimer’s
disease and Parkinson’s disease, is expected to increase strongly in the coming decades. Though great
efforts have been paid on research, neurodegenerative diseases remain as urgent unresolved problems in
modern day medicine. At present, there is no cure for these diseases, resulting in death of neuron cells.
Generally, the disease mechanisms are not fully understood and are thought to be related to genetics,
protein misfolding/degradation or mitochondrial dysfunction etc. This introduces further complexity in the
search for therapeutic approaches for these diseases.
In most neurodegenerative diseases, the blood–brain barrier (BBB) becomes a hurdle in effective drug
delivery. Small molecules or biologics need to be engineered to cross the BBB and reach their target in
sufficient concentrations to elicit a pharmacodynamics response. The drug concentration in the brain is
tricky to determine, while behavioral assessment methods are used as surrogates for pharmacodynamics
effects. In this context, it could be challenging to establish an unambiguous pharmacokinetics/pharmacodynamics relationship.
In this special issue, some papers reviewed the mechanisms, treatment approaches, animal models
used for Alzheimer’s disease. A paper reported a trend model for Alzheimer’s disease mortality. Moreover,
two review papers discussed BBB permeability and delivery in traumatic brain injury and in insulin delivery
for Alzheimer’s disease, respectively. Other papers dealt with cognitive deficits. Finally, two other papers
discussed the use of nanotechnology platform in Parkinson’s disease and the interactions of prion protein
with metal ions.
For the first time, ADMET & DMPK devotes a special issue on medical research/applications in a
particular therapeutic area, with the aims to capture some of the current views and new achievements in
neurodegenerative diseases. It is nice to see some papers discussing cross-disciplinary research and new
thoughts to tackle these diseases. Hopefully, we will call for more special issues aligned to other
therapeutic areas in due course.
doi: 10.5599/admet.3.3.217
154